{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:27:48Z","timestamp":1789648068433,"version":"4.0.0"},"reference-count":21,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2016,6,15]]},"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In recent years, multiparameter flow cytometry has been increasingly recognised as an important tool in diagnosis of myelodysplastic syndrome and acute myeloid leukaemia (AML). Assessment of myeloid and monocytic \u2018immunophenotypic\u2019 dysplasia by flow cytometry in de novo AML has not been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>97 cases of de novo AML cases were identified and reviewed by three hematopathologists. \u2018Immunophenotypic\u2019 dysplasia was assessed on blasts, monocytes and granulocytes by mean fluorescence intensity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using the 2008 WHO classification criteria, there were 53 AML-not otherwise specified (NOS) (55%) and 28 AML with myelodysplasia-related changes (AML-MRC) (29%), while 16 cases were ambiguous as to AML-MRC status due to limited maturing cells for morphologic but adequate events number for immunophenotypic evaluation (AML-not evaluable, 16%). Compared with AML-NOS, granulocytic cells in AML-MRC had higher CD33 expression but lower CD45, CD11b and CD15. Monocytes in AML-MRC had lower expression of CD14, CD56 and CD45. Morphologic dysplasia was associated with significantly lower granulocytic forward scatter, side scatter and CD10 but higher CD33 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that the workup of AML cases should include flow cytometric assessment of granulocytes and monocytes. This analysis can aid a morphologic impression of multilineage dysplasia in distinguishing AML-MRC from AML-NOS, especially in cases with limited maturing myeloid cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2016-203863","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T23:49:04Z","timestamp":1467935344000},"page":"109-115","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category"],"prefix":"10.1136","volume":"70","author":[{"given":"Olga K","family":"Weinberg","sequence":"first","affiliation":[{"name":"Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"2025121407010072000_70.2.109.1","unstructured":"Swerdlow SH , Campo E , Harris NL , et al ., eds. WHO classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyons, France IARC Press, 2008: 109\u201338."},{"key":"2025121407010072000_70.2.109.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-182782"},{"key":"2025121407010072000_70.2.109.3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.55"},{"key":"2025121407010072000_70.2.109.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2768"},{"key":"2025121407010072000_70.2.109.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-153700"},{"key":"2025121407010072000_70.2.109.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-098764"},{"key":"2025121407010072000_70.2.109.7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.005801"},{"key":"2025121407010072000_70.2.109.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.979"},{"key":"2025121407010072000_70.2.109.9","first-page":"675","article-title":"New methodologic approaches for immunophenotyping acute leukemias","volume":"86","author":"Basso","year":"2001","journal-title":"Haematologica"},{"key":"2025121407010072000_70.2.109.10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/cyto.b.20633","article-title":"Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia","volume":"82","author":"Hoffmann","year":"2012","journal-title":"Cytometry B Clin Cytom"},{"key":"2025121407010072000_70.2.109.11","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPRL6XSVFMLH9V"},{"key":"2025121407010072000_70.2.109.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1266-3"},{"key":"2025121407010072000_70.2.109.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2010.02694.x"},{"key":"2025121407010072000_70.2.109.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.09.019"},{"key":"2025121407010072000_70.2.109.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2082-4"},{"key":"2025121407010072000_70.2.109.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401067"},{"key":"2025121407010072000_70.2.109.17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.217"},{"key":"2025121407010072000_70.2.109.18","first-page":"3","article-title":"Granulocyte, monocyte and blast immunophenotype abnormalities in acute myeloid leukemia with myelodysplasia-related changes","volume":"44","author":"Ayar","year":"2014","journal-title":"Ann Clin Lab Sci"},{"key":"2025121407010072000_70.2.109.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3826"},{"key":"2025121407010072000_70.2.109.20","doi-asserted-by":"crossref","unstructured":"Grimwade D , Freeman SD . Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d? Hematology Am Soc Hematol Educ Program 2014:222\u201333.doi:10.1182\/asheducation-2014.1.222","DOI":"10.1182\/asheducation.V2014.1.222.3884425"},{"key":"2025121407010072000_70.2.109.21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.109"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2016-203863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:01:08Z","timestamp":1765724468000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2016-203863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,20]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1136\/jclinpath-2016-203863"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2016-203863","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}